Shattuck Labs’ DR3 Antibody Strategy Draws Focus at Cantor Conference

At the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, Shattuck Laboratories (STTK) CEO Taylor emphasized the company’s exclusive focus on blocking the DR3 receptor, a pathway critical to its pipeline. With a market capitalization of $633 million and a 223% year-over-year stock surge, Shattuck’s financial position remains robust, holding more cash than debt and maintaining a current ratio of 27.59. The biotech’s lead candidate, SL-325—a DR3 antagonist monoclonal antibody—is positioned for a pivotal Phase IIb trial in Crohn’s disease, using an intravenous formulation in a treat-through design to evaluate endoscopic and clinical responses across three active dose arms and a placebo group. Preliminary data suggest a low ADA (anti-drug antibody) rate of 3.7%, significantly outperforming competitors like Merck, Roche, and Sanofi, whose TL1A antibodies report rates as high as 48%. SL-325 achieves receptor saturation at just 0.1 mg/kg in early-phase trials, with stable occupancy maintained at 1 mg/kg over three months. Subcutaneous bioavailability in monkey studies reached 80% or more, offering potential for improved patient compliance. Concurrently, Shattuck’s SL-846—a DR3/IL-23R bispecific antibody—is advancing through preclinical toxicology, with data expected at UEGW next month. The company’s competitive edge lies in its unmatched disclosure of a DR3-blocking antibody, a niche not shared by peers like Human Genome Sciences or Amgen. Shattuck’s strategy for hidradenitis suppurativa (HS) is also poised for announcement soon, further diversifying its therapeutic focus beyond Crohn’s disease.